This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.

Inclusion Criteria:

1. Patient consent

2. Males and females aged 18 years old or older

3. PH-ILD diagnosis:

   • Confirmed diagnosis of Group 3 PH by Right Heart Catheterization (RHC):

     - mPAP > 20 mmHg with PAWP ≤ 15 mmHg and PVR ≥ 2 WU and

   • Confirmed diagnosis of diffuse parenchymal lung disease based on imaging (any form of ILD or CPFE)

Exclusion Criteria:

1. Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD
2. Use of concomitant PAH drugs contraindicated for PH-ILD (ambrisentan and riociguat)
3. Use of any concomitant investigational drug